Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population
María G. Crespo‐Leiro(Complexo Hospitalario Universitario A Coruña), Brian Drachman(Penn Presbyterian Medical Center), Pablo García‐Pavía(Universidad Francisco de Vitoria), Thibaud Damy(Amyloidosis Foundation), D. Delgado(University Health Network), Ben Ebede(Pfizer (United States)), Michael G. Hanna(National Hospital for Neurology and Neurosurgery), Franca S. Angeli(Pfizer (United States)), Matthew J. Maurer(Mayo Clinic in Arizona)
Cited by 0
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k